Viyash Scientific Ltd Q4 FY26 Earnings Analysis

- API business expected to grow at a double-digit rate going forward, driven by quality APIs (human and animal health) and new approvals coming this year and next (Page 17). - Formulation business also anticipated to grow strongly, particularly animal health formulations with significant R&D and capex expansion (Page 17). - Targeting overall revenue growth of around 15% annually over the next few years (Page 15). - Animal health segment showing strong growth after years of being stable; run rate increased from ~INR350 crores to INR400 crores, with further growth expected (Page 4). - CDMO business projected to grow 30-40% next year, supported by 8-10 innovator clients and multiple product approvals underway (Page 5). - Focus on expanding into European companion animal market (~$1 billion) and preparing for entry into the U.S. market in coming years (Pages 11-13). - Overall revenue for FY26 grew 13.8%; formulations up 18% and API up 8% (Page 5).

- EBITDA expected to grow from INR700 crores to around INR1,000 crores in next 2-3 years, targeting FY27/FY28. - Annual revenue growth rate approximated at 15%, with potential for double-digit growth in API and formulation segments. - Depreciation expected to reduce from INR100 crores to about INR35 crores next year due to amortization of intangibles going away. - Profit before tax and profit after tax showed significant improvement in FY26, reflecting turnaround and strong earnings momentum. - Synergies from merger expected to contribute INR125-150 crores annually over next 12-18 months, boosting margins and profitability. - R&D and capex investments will increase, especially in animal health formulation, supporting sustainable growth. - Tax rate to stabilize around 26-27% from FY27 onwards, aiding net profit visibility. - Management confident in maintaining current margin levels despite increased investments.

- Significant capex planned for capacity expansion, especially in animal health formulation and finished product formulation (human health and companion animals). - Investment in R&D expansion with focus on adding more scientists, particularly in specialized human health formulation and animal health formulation teams. - Development of dedicated potent lab for oncology product R&D expected to be ready soon (this or next quarter). - Manufacturing expansion ongoing in Spain and debottlenecking at Turkey manufacturing to support future growth. - Capex already done in Viyash for capacity increase, awaiting approvals to realize further synergy benefits. - Depreciation impact from capex expected to be stable; new capex unlikely to significantly increase overall depreciation expense going forward. - Continued strategic investments to develop new API products, especially to replace intermediates and for new product approvals between FY28-FY29.

- The transcript does not mention any current or planned fundraising through debt or equity. - The company emphasizes a strong balance sheet with healthy liquidity and comfortable leverage, providing flexibility for growth. - One key priority for FY27 includes further reducing debt and maximizing cash flow generation. - There is no specific discussion or indication of raising new debt or equity during the conference. - The focus seems to be on internal cash flow, operational improvements, and efficient capital allocation rather than new fundraising.

The transcript does not explicitly mention specific figures or details related to the current or expected order book or pending orders for Viyash Scientific Limited. However, relevant points indicating business outlook and growth include: - The CDMO business is working with 8 to 10 large innovator clients with several product approvals expected starting end of the current year. - The company anticipates a reasonable number of product approvals this year, supporting top-line and bottom-line growth. - Growth in the animal health segment, especially companion animal generics in Europe and other markets, is increasing with a $1 billion addressable opportunity. - Expected EBITDA growth targets point to a CAGR of around 15%, suggesting increasing business volume. - Management focuses on expanding manufacturing and R&D capacity to support anticipated demand growth. - The company reports ongoing synergies and integration benefiting operational performance and growth. No direct mention of the order book status or pending orders is made.